ライフサイエンスコーパス: flexible sigmoidoscopy

1 with the new Medicare reimbursement rate for flexible sigmoidoscopy.

2 roximal colon following a positive screening flexible sigmoidoscopy.

3 nts with distal adenomas or cancers found at flexible sigmoidoscopy.

4 ce mortality: fecal occult blood testing and flexible sigmoidoscopy.

5 40 674 (71%) people underwent flexible sigmoidoscopy.

6 lonoscopies and are 10-fold less common with flexible sigmoidoscopy.

7 l occult blood testing (FOBT), but not about flexible sigmoidoscopy.

8 pies, 6.1 million upper endoscopies, 313,000 flexible sigmoidoscopies, 178,400 upper endoscopic ultra

9 could increase to approximately 9.5 million flexible sigmoidoscopies (95% CI, 8.4-10.5) and 22.4 mil

10 al occult blood test screening plus periodic flexible sigmoidoscopy about every 5 years for asymptoma

11 If flexible sigmoidoscopy alone had been performed, advance

12 esting (FIT), multitarget stool DNA testing, flexible sigmoidoscopy alone or with FIT, computed tomog

13 eir lesions identified if they had undergone flexible sigmoidoscopy alone, as compared with 66.3 perc

14 d have been identified if they had undergone flexible sigmoidoscopy alone.

15 er additional life-year gained compared with flexible sigmoidoscopy alone.

16 approximately 2.8 million (95% CI, 2.4-3.1) flexible sigmoidoscopies and 14.2 million (95% CI, 12.1-

17 Approximately 2.8 million flexible sigmoidoscopies and 14.2 million colonoscopies

18 they could perform an additional 6.7 million flexible sigmoidoscopies and 8.2 million colonoscopies i

19 eening group (10,283 randomized to receive a flexible sigmoidoscopy and 10,289 to receive flexible si

20 ntervention group), 83.5% underwent baseline flexible sigmoidoscopy and 54.0% were screened at 3 or 5

21 le sigmoidoscopy or combination of once-only flexible sigmoidoscopy and fecal occult blood testing (F

22 nce-only flexible sigmoidoscopy screening or flexible sigmoidoscopy and FOBT reduced colorectal cance

23 tween the flexible sigmoidoscopy only vs the flexible sigmoidoscopy and FOBT screening groups.

24 flexible sigmoidoscopy and 10,289 to receive flexible sigmoidoscopy and FOBT).

25 We created a new library of 57 videos of flexible sigmoidoscopy and stratified them based on dise

26 The strategies included conventional serial flexible sigmoidoscopy and two different APC gene testin

27 d performance of fecal occult blood testing, flexible sigmoidoscopy, and barium enema.

28 uctible health plan members had colonoscopy, flexible sigmoidoscopy, and DCBE less often (ratio of ch

29 ests subject to the deductible (colonoscopy, flexible sigmoidoscopy, and DCBE).

30 Incidence rates of colonoscopy, flexible sigmoidoscopy, and fecal occult blood test were

31 ced nurse endoscopists may perform screening flexible sigmoidoscopy as safely and as effectively as g

32 ven, performance of endoscopic ultrasound or flexible sigmoidoscopy at 3- to 6-month intervals for th

33 Participants received flexible sigmoidoscopy at baseline and 3 or 5 y after.

34 ears were randomly assigned to usual care or flexible sigmoidoscopy at baseline and again at 3 years

35 ategies included no evaluation, colonoscopy, flexible sigmoidoscopy, barium enema, anoscopy, or any f

36 The cost of flexible sigmoidoscopy-based screening for colorectal ca

37 ncer) in men would be missed with the use of flexible sigmoidoscopy but detected by colonoscopy.

38 he Medicare reimbursement rate for screening flexible sigmoidoscopy (code 45330, $87.84).

39 ently available methods (fecal occult blood, flexible sigmoidoscopy, colonoscopy, and double contrast

40 cal occult blood testing in the past year or flexible sigmoidoscopy, colonoscopy, or barium enema in

41 The incremental cost-effectiveness of flexible sigmoidoscopy compared with no evaluation or wi

42 effectiveness of screening with colonoscopy, flexible sigmoidoscopy, computed tomography colonography

43 INTERPRETATION: A single flexible sigmoidoscopy continues to provide substantial

44 Colonoscopy, flexible sigmoidoscopy, CTC, and stool tests have differ

45 negative individuals, use of colonoscopy and flexible sigmoidoscopy decreased significantly between p

46 iterature regarding the role of colonoscopy, flexible sigmoidoscopy, endoscopic ultrasound, fecal tes

47 very 2 years, colonoscopy every 10 years, or flexible sigmoidoscopy every 10 years plus fecal immunoc

48 s, the FIT-fecal DNA test every 3 years, and flexible sigmoidoscopy every 5 to 10 years.

49 Annual Hemoccult II and flexible sigmoidoscopy every 5 years alone were less eff

50 al occult blood testing (FOBT) combined with flexible sigmoidoscopy every 5 years and using colonosco

51 , annual screening with a sensitive FOBT, or flexible sigmoidoscopy every 5 years with a midinterval

52 strategies: annual fecal occult blood tests, flexible sigmoidoscopy every 5 years, or colonoscopy eve

53 years and older who had a negative screening flexible sigmoidoscopy examination between 1994 and 1996

54 ore costly and less effective than FOBT plus flexible sigmoidoscopy, except in the CRC-SPIN model ass

55 Cost analysis of flexible sigmoidoscopy, followed by colonoscopy as warra

56 analyses have only reported follow-up after flexible sigmoidoscopy for a maximum of 12 years.

57 tients with primary rectal cancer undergoing flexible sigmoidoscopy for response assessment after neo

58 o investigate how endoscopist performance at flexible sigmoidoscopy (FS) affects adenoma detection an

59 Flexible sigmoidoscopy (FS) is recommended for mass scre

60 f computed tomographic (CT) colonography and flexible sigmoidoscopy (FS) screening and the factors pr

61 yielded varying estimates of the benefit of flexible sigmoidoscopy (FS) screening for colorectal can

62 symptomatic subjects who underwent screening flexible sigmoidoscopy (FSG) within the Prostate, Lung,

63 d on the size of the abnormality detected at flexible sigmoidoscopy (FSG).

64 ible sigmoidoscopy with anoscopy followed by flexible sigmoidoscopy if needed, the middle 95th percen

65 Lesions were considered detectable by flexible sigmoidoscopy if they were in the distal colon

66 This study examines the cost of performing flexible sigmoidoscopy in a primary care practice and co

67 ore costly and less effective than FOBT plus flexible sigmoidoscopy in all three models in both 100%

68 fecal occult blood test in the past 2 years, flexible sigmoidoscopy in the past 5 years, or colonosco

69 Flexible sigmoidoscopy is a safe and practical test and,

70 The use of nurse endoscopists to perform flexible sigmoidoscopy is expanding, increasing the avai

71 cal colonoscopy beyond the expected reach of flexible sigmoidoscopy is very low and may not justify t

72 creening, although current techniques (e.g., flexible sigmoidoscopy) lack the requisite sensitivity.

73 Screening with flexible sigmoidoscopy may reduce mortality rates from c

74 al trials (RCTs) evaluating 1-time or 2-time flexible sigmoidoscopy (n = 458,002) were associated wit

75 We evaluated the effect of screening with flexible sigmoidoscopy on colorectal-cancer incidence an

76 There was no difference between the flexible sigmoidoscopy only vs the flexible sigmoidoscop

77 The capacity for screening with flexible sigmoidoscopy or colonoscopy depends on the pro

78 s beginning at age 50, using either FOBT and flexible sigmoidoscopy or colonoscopy in each racial or

79 nd a fecal test in the previous 2 years or a flexible sigmoidoscopy or colonoscopy in the previous 10

80 total of 8207 practices reported performing flexible sigmoidoscopy or colonoscopy in the United Stat

81 Poor patient attendance to scheduled flexible sigmoidoscopy or colonoscopy may contribute to

82 rs to screen the unscreened population using flexible sigmoidoscopy or colonoscopy.

83 nts were randomized 1:1 to receive once-only flexible sigmoidoscopy or combination of once-only flexi

84 ed between 2012 and 2019 to either once-only flexible sigmoidoscopy or FIT screening every second yea

85 Fecal occult blood tests (FOBTs), flexible sigmoidoscopy, or colonoscopy screening beginni

86 -laxative computed tomographic colonography, flexible sigmoidoscopy, or colonoscopy).

87 lt blood testing (FOBT) but not colonoscopy, flexible sigmoidoscopy, or double-contrast barium enema

88 3: ACP recommends using a stool-based test, flexible sigmoidoscopy, or optical colonoscopy as a scre

89 AP screening strategy depends on the cost of flexible sigmoidoscopy, patient age when screening start

90 atients were randomized to undergo screening flexible sigmoidoscopy performed by a nurse endoscopist

91 n, and the incidence of complications during flexible sigmoidoscopy performed by nurse endoscopists a

92 The incremental cost-effectiveness of flexible sigmoidoscopy plus barium enema compared with c

93 A strategy of flexible sigmoidoscopy plus barium enema yielded the gre

94 eline-concordant screening with colonoscopy, flexible sigmoidoscopy plus either sensitive unrehydrate

95 Screening flexible sigmoidoscopy reduces incidence and mortality o

96 eports, 20,748 colonoscopy reports, and 9767 flexible sigmoidoscopy reports to the central databank.

97 nalyses is that the time required to perform flexible sigmoidoscopy represents an opportunity cost be

98 ancer incidence and mortality after a single flexible sigmoidoscopy screening and 17 years of follow-

99 lorectal cancer incidence and mortality from flexible sigmoidoscopy screening are sustained over the

100 55 to 74 years, randomly assigned to receive flexible sigmoidoscopy screening as part of the Prostate

101 We tested the hypothesis that only one flexible sigmoidoscopy screening between 55 and 64 years

102 We analysed data from six pilot flexible sigmoidoscopy screening centres to examine fact

103 In Norway, once-only flexible sigmoidoscopy screening or flexible sigmoidosco

104 We did a retrospective analysis of flexible sigmoidoscopy screening procedures performed in

105 Key performance indicators for flexible sigmoidoscopy screening should be defined, incl

106 Flexible Sigmoidoscopy Screening Trial (overall, 12.1%;

107 In this multicentre randomised trial (UK Flexible Sigmoidoscopy Screening Trial), done between No

108 gned (1:2) to an intervention group (offered flexible sigmoidoscopy screening) or a control group (no

109 allocated to the intervention group (offered flexible sigmoidoscopy screening) or the control group (

110 ho have a small tubular adenoma on screening flexible sigmoidoscopy should undergo colonoscopic exami

111 started in England in 2013, offering one-off flexible sigmoidoscopy to all men and women aged 55 year

112 rectal and Ovarian cancer screening trial of flexible sigmoidoscopy versus usual care (55-74 years ol

113 002), intention to screen with 1- or 2-time flexible sigmoidoscopy vs no screening was associated wi

114 Screening with flexible sigmoidoscopy was associated with a significant

115 The diagnostic yield of flexible sigmoidoscopy was calculated by estimating the

116 Flexible sigmoidoscopy was most commonly performed for r

117 Fecal occult blood testing or flexible sigmoidoscopy was ordered for 47.2% of interven

118 ociated with the performance of office-based flexible sigmoidoscopy were derived from the published l

119 onography, double-contrast barium enema, and flexible sigmoidoscopy were rarely performed.

120 Participants were examined by flexible sigmoidoscopy when the study began and then wer

121 probabilistic sensitivity analysis comparing flexible sigmoidoscopy with anoscopy followed by flexibl

122 ng evidence shows that periodic screening by flexible sigmoidoscopy with appropriate referral of pati

123 ursement may limit the adoption of screening flexible sigmoidoscopy with or without biopsy in primary

124 esting (FIT), multitarget stool DNA testing, flexible sigmoidoscopy with or without stool testing, co

125 screening of Americans 50 years and older by flexible sigmoidoscopy with referral of subjects with ad

126 to 74 years of age either to screening with flexible sigmoidoscopy, with a repeat screening at 3 or

127 es were used, the physician's total cost for flexible sigmoidoscopy without biopsy was $86.86, which

128 mental cost-effectiveness ratios ranged from flexible sigmoidoscopy yielding an increased life expect